AMICUS THERAPEUTICS INC (FOLD)
US03152W1099 - Common Stock
7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps
These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on.
Amicus Therapeutics files to sell 2.5M shares for holders (NASDAQ:FOLD)
Selling stockholders of Amicus Therapeutics (FOLD) to offer 2.5 million shares for sale, with the company not receiving any proceeds.
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
3Q 2023 Total Revenue of $103.5M, a 27% Increase Year-Over-Year and 22% at CER Galafold® Quarterly Revenue Surpasses $100M for the First Time ...
Commit To Buy Amicus Therapeutics At $10, Earn 18.5% Annualized Using Options
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
PRINCETON, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming...
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and...
Notable Friday Option Activity: GME, FOLD, TGT
Oversold Conditions For Amicus Therapeutics (FOLD)
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four posters...
Amicus in pact with Blackstone for $430M financing (NASDAQ:FOLD)
Amicus Therapeutics secures $430M in financing through a loan arrangement and equity offering with Blackstone. Read more here.
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule Blackstone to also Purchase $30M of Amicus Common Stock PRINCETON,...
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease
/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates...
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults...
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.
Amicus closes up 5% as it expects approval of Pompe disease therapy (NASDAQ:FOLD)
Amicus Therapeutics expects imminent approval of its Pompe disease treatment, AT-GAA, as indicated in an updated corporate presentation.
Amicus Therapeutics (FOLD) Shares Cross Below 200 DMA
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming...
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across...
WuXi Biologics Reports Solid 2023 Interim Results
Revenue Increased by 17.8% Y-o-Y to RMB8,492.0 Million Adjusted Net Profit Rose by 0.4% to RMB2,925.6 Million Non-COVID Revenue Achieved 59.7% Y-o-Y Growth,...
Amicus Therapeutics appoints CFO (NASDAQ:FOLD)
Biotechnology company Amicus Therapeutics (FOLD) said on Monday that Simon Harford has been appointed CFO, effective immediately.
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global...
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain National Institute for...
Amicus Therapeutics reports mixed Q2 earnings; updates FY23 outlook (NASDAQ:FOLD)
Amicus Therapeutics press release (FOLD): Q2 GAAP EPS of -$0.15 misses by $0.04.Revenue of $94.5M (+17.1% Y/Y) beats by $4.63M.Cash, cash equivalents, and marketable securities...
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold® Revenue Growth Guidance to 14%-18% at CER EU Launch of Pombiliti® + Opfolda®...